Axsome Therapeutics Inc.

103.01
-1.45 (-1.39%)
At close: Apr 21, 2025, 3:59 PM
103.31
0.29%
Pre-market: Apr 22, 2025, 04:24 AM EDT

Axsome Therapeutics Statistics

Share Statistics

Axsome Therapeutics has 48.77M shares outstanding. The number of shares has increased by 2.67% in one year.

Shares Outstanding 48.77M
Shares Change (YoY) 2.67%
Shares Change (QoQ) 0.63%
Owned by Institutions (%) 77.28%
Shares Floating 40.08M
Failed to Deliver (FTD) Shares 8
FTD / Avg. Volume < 0.01%

Short Selling Information

The latest short interest is 5.15M, so 10.56% of the outstanding shares have been sold short.

Short Interest 5.15M
Short % of Shares Out 10.56%
Short % of Float 12.63%
Short Ratio (days to cover) 9.16

Valuation Ratios

The PE ratio is -14.11 and the forward PE ratio is 42.99. Axsome Therapeutics's PEG ratio is -1.03.

PE Ratio -14.11
Forward PE 42.99
PS Ratio 10.51
Forward PS 1.9
PB Ratio 71.1
P/FCF Ratio -31.5
PEG Ratio -1.03
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Axsome Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.11, with a Debt / Equity ratio of 3.36.

Current Ratio 2.11
Quick Ratio 2.04
Debt / Equity 3.36
Debt / EBITDA -0.68
Debt / FCF -1.49
Interest Coverage -42.71

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $564.7K
Profits Per Employee $-420.52K
Employee Count 683
Asset Turnover 0.68
Inventory Turnover 2.12

Taxes

Income Tax 85K
Effective Tax Rate -0.03%

Stock Price Statistics

The stock price has increased by 44.88% in the last 52 weeks. The beta is 0.88, so Axsome Therapeutics's price volatility has been higher than the market average.

Beta 0.88
52-Week Price Change 44.88%
50-Day Moving Average 118.82
200-Day Moving Average 97.93
Relative Strength Index (RSI) 40.18
Average Volume (20 Days) 1.02M

Income Statement

In the last 12 months, Axsome Therapeutics had revenue of 385.69M and earned -287.22M in profits. Earnings per share was -5.99.

Revenue 385.69M
Gross Profit 352.39M
Operating Income -280.56M
Net Income -287.22M
EBITDA -280.56M
EBIT -280.56M
Earnings Per Share (EPS) -5.99
Full Income Statement

Balance Sheet

The company has 315.35M in cash and 191.53M in debt, giving a net cash position of 123.82M.

Cash & Cash Equivalents 315.35M
Total Debt 191.53M
Net Cash 123.82M
Retained Earnings -1.12B
Total Assets 568.5M
Working Capital 254.96M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -128.41M and capital expenditures -270K, giving a free cash flow of -128.68M.

Operating Cash Flow -128.41M
Capital Expenditures -270K
Free Cash Flow -128.68M
FCF Per Share -2.69
Full Cash Flow Statement

Margins

Gross margin is 91.37%, with operating and profit margins of -72.74% and -74.47%.

Gross Margin 91.37%
Operating Margin -72.74%
Pretax Margin -74.45%
Profit Margin -74.47%
EBITDA Margin -72.74%
EBIT Margin -72.74%
FCF Margin -33.36%

Dividends & Yields

AXSM does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for AXSM is $167, which is 62.1% higher than the current price. The consensus rating is "Buy".

Price Target $167
Price Target Difference 62.1%
Analyst Consensus Buy
Analyst Count 15
Stock Forecasts

Scores

Altman Z-Score 2.79
Piotroski F-Score 3